/

ARWR

Arrowhead Pharmaceuticals, Inc.Open

58.84−1.89 −3.11%USD

NasdaqGS · as of Oct 13, 12:41 ET · 15m delay

Open

60.04

Prev close

60.73

Day range

58.2260.73

52-week range

34.6195.49

Volume

739.07K0.39×

Mkt cap

8.31B

P/E ttm

—

Fwd P/E

-11.93

EPS ttm

-2.28

Div yield

0.00%

Earnings

Aug 4, 2026

From 52w high

−38.38%

Price Chart

Yahoo Finance · delayed

ARWROct 13, 2026O 60.04H 60.73L 58.22C 58.84−1.89 (−3.11%)Vol 739.07K

SMA 5077.36
SMA 20072.26

1Y change +66.17% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ARWR Arrowhead Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −4.39%
1 month: −28.98%
3 months: −18.18%
6 months: −11.77%
Year to date: −11.37%
1 year: +62.32%

Valuation & ownership

Market cap: 8.31B
Enterprise value: 8.36B
P/E (ttm): —
Forward P/E: -11.93
PEG ratio: —
Price / book: 17.84
Price / sales (ttm): 12.41
EV / EBITDA: -41.67
EPS (ttm): -2.28
EPS (forward): -4.93
Beta (5y monthly): 1.30
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 141.25M
Float: 122.45M
Short % of float: 10.60%
Short ratio (days): 4.77
Held by insiders: 3.66%
Held by institutions: 85.39%
Avg volume (3m): 1.88M
50-day average: 77.90
200-day average: 72.32
52-week change: +62.32%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 27.2
vs 50-day SMA: −23.94%
vs 200-day SMA: −18.58%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 4.94%
Realised vol (20d, ann.): 48.5%
From 52-week high: −38.38%
From 52-week low: +70.01%

ANR

Analyst Consensus

13 analysts

Consensus

Strong buy

1.43 on a 1 (strong buy) – 5 (sell) scale

Mean target

107.23

+82.24% implied

Low 74.00Median 104.00High 126.00

Recommendation trend

Now13 / 1 / 0
1m ago / 1 /

DES

About Arrowhead Pharmaceuticals, Inc.

Yahoo Finance profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 711
Headquarters: Pasadena, CA, United States
Website: arrowheadpharma.com
Officers: Dr. Christopher R. Anzalone Ph.D. Chairman, CEO & President

SEAS

Seasonality · ARWR

2007–2026 · monthly returns

Strongest month Nov +7.02%Weakest month Oct −1.20%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	4.4	-8.7	-0.9	17.2	6.0	4.6	3.9	-2.7	-20.6	-10.1			−11.4%
2025	5.7	-4.9	-32.6	9.0	15.7	-1.7	0.0	39.4	56.6	22.9	24.3	26.0	+253.1%
2024	4.9	0.0	-10.9	-20.9	1.5	13.2	9.9	-16.6	-18.7	-0.7	35.4	-27.8	−38.6%
2023	-13.7	-7.7	-21.4	39.4	-2.8	3.6	-3.2	-19.9	-2.8	-8.5	-13.8	44.3	−24.6%
2022	-20.4	-16.6	4.5	-10.6	-18.9	5.5	20.8	-6.6	-16.8	5.3	-7.5	26.0	−38.8%
2021	0.6	3.2	-16.8	9.7	-0.2	14.1	-16.3	-3.1	-7.0	2.2	9.8	-5.4	−13.6%
2020	-33.9	-15.6	-18.6	19.7	-6.4	34.0	-0.3	-1.9	1.9	33.1	9.1	22.7	+21.0%
2019	13.7	38.2	-6.0	-2.0	31.9	11.8	9.7	17.6	-17.5	42.1	82.3	-13.1	+410.7%
2018	67.9	4.9	11.3	-11.0	67.0	26.9	7.1	1.3	29.9	-33.6	14.2	-14.5	+237.5%
2017	25.2	16.5	-18.1	-16.2	-7.1	12.5	8.6	59.1	54.6	-15.9	-1.9	3.1	+137.4%
2016	-43.4	12.1	23.6	20.1	5.9	-13.2	12.0	16.3	6.1	-21.1	-75.2	7.6	−74.8%
2015	-14.5	19.3	-10.2	2.0	-8.7	13.5	-13.6	-4.0	-2.9	-10.6	22.7	-2.7	−16.7%
2014	41.4	26.7	-15.5	-33.5	15.2	13.8	-11.6	15.2	1.4	-55.9	-10.7	26.8	−32.0%
2013	-9.3	11.3	1.0	-5.5	6.8	-9.1	88.5	10.1	37.1	23.0	17.6	31.8	+407.0%
2012	12.9	14.0	18.4	-9.2	-30.9	-4.0	-3.6	-27.6	-2.2	-3.8	-12.3	-3.2	−48.9%
2011	-2.8	-21.8	10.3	-19.7	-10.3	-5.6	3.9	3.8	-29.1	29.2	22.4	-32.1	−53.2%
2010	7.5	-7.0	115.1	34.2	-11.8	-18.5	6.4	-22.2	15.4	-5.9	-3.8	-5.8	+68.9%
2009	-5.4	-55.2	43.6	14.3	-18.8	-15.4	10.2	-4.3	43.3	-21.8	15.4	-11.7	−42.4%
2008	-16.9	-22.3	16.0	-5.3	-7.8	0.8	-15.3	-17.1	-40.6	15.4	6.7	-28.1	−75.7%
2007	-6.0	-7.9	18.0	44.0	18.0	-33.8	-10.3	8.2	3.5	-18.2	-1.2	-7.4	−13.7%

INSD

Insider Activity · ARWR

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

11.9K shares

Sells, 6 months

39.7K shares

Net shares

−27.8K

Net change in insider shares

−0.50%

Date	Insider	Transaction	Shares	Value
Aug 17, 2026	Olukotun Adeoye YDirector	Sale at price 86.96 per share.	2K	$173.92K
Aug 17, 2026	Perry Michael SDirector	Sale at price 87.30 per share.	11.6K	$1.01M
Jun 14, 2026	Cohen Matthew GregoryDirector	Stock Award(Grant) at price 0.00 per share.	11.9K	—
May 11, 2026	Lu Hongbo BDirector	Sale at price 76.88 per share.	3K	$228.33K
Apr 22, 2026	Hamilton James COfficer	Sale at price 75.00 per share.	10K	$750.00K
Apr 21, 2026	Apel Daniel JosephChief Financial Officer	Sale at price 70.11 - 71.92 per share.	13.1K	$934.28K
Mar 4, 2026	Hamilton James COfficer	Sale at price 64.19 per share.	10K	$641.90K
Jan 5, 2026	O'Brien Patrick CChief Operating Officer	Stock Gift at price 0.00 per share.	2.5K	—
Jan 5, 2026	O'Brien Patrick CChief Operating Officer	Stock Award(Grant) at price 0.00 per share.	75K	—
Jan 5, 2026	Hamilton James COfficer	Stock Award(Grant) at price 0.00 per share.	75K	—
Jan 5, 2026	Apel Daniel JosephChief Financial Officer	Stock Award(Grant) at price 0.00 per share.	75K	—
Jan 4, 2026	O'Brien Patrick CChief Operating Officer	Sale at price 61.12 - 68.00 per share.	49.5K	$3.12M
Jan 4, 2026	Hamilton James COfficer	Sale at price 61.24 - 68.00 per share.	40.2K	$2.53M
Jan 1, 2026	Anzalone Christopher RichardChief Executive Officer	Sale at price 65.88 - 66.39 per share.	13.2K	$871.70K
Dec 30, 2025	O'Brien Patrick CChief Operating Officer	Stock Gift at price 0.00 per share.	2.8K	—
Dec 28, 2025	Anzalone Christopher RichardChief Executive Officer	Sale at price 68.69 - 69.33 per share.	51.7K	$3.58M
Dec 28, 2025	Anzalone Christopher RichardChief Executive Officer	Conversion of Exercise of derivative security at price 6.15 per share.	51.7K	$318.12K
Dec 25, 2025	Ferrari MauroDirector	Sale at price 70.00 per share.	7.5K	$527.10K
Dec 21, 2025	Anzalone Christopher RichardChief Executive Officer	Sale at price 66.67 - 68.85 per share.	26K	$1.77M
Dec 18, 2025	Olukotun Adeoye YDirector	Sale at price 66.70 - 68.48 per share.	10K	$676.62K

13F

Investors Holding ARWR

latest 13F filings of 29 followed managers

Investors holding ARWR
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$38.2M	0.05%	468.92K	−55%	Q2 2026
Oaktree Capital · Howard Marks	$11.0M	0.15%	9.15M	New	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ARWR

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ARWR

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Arrowhead Pharmaceuticals, Inc.

Seasonality · ARWR

Insider Activity · ARWR

Congress Trades · ARWR

Investors Holding ARWR

Investors Holding ARWR

Congress Trades · ARWR

Insider Activity · ARWR

Seasonality · ARWR

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Arrowhead Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News